← Back to TNDM filing summaryOriginal filing text · Part I
Item 3 — Quantitative and Qualitative Disclosures About Market Risk
Tandem Diabetes Care, Inc. · 10-Q · Q2 FY2026 · Period ended Jun 30, 2026
View complete filing on SEC EDGAR ↗This is the extracted source text from the SEC filing. Formatting may differ from the original document.
There were no material changes to our quantitative and qualitative disclosures about market risk during the six months ended June 30, 2026 contained in Part II, Item 7A of our Annual Report, other than our entry into foreign currency forward contracts to mitigate the impact of foreign currency exchange rate fluctuations on the portions of our revenue and operating expenses and contractual payment obligations that are denominated in currencies other than the U.S. dollar. See Note 9, “Derivatives” to the unaudited condensed consolidated financial statements included in this Quarterly Report for more information.